Skip to main content
Download PDF

IL-31, itch and hematological malignancies

Clinical and Molecular Allergy volume 19, Article number: 8 (2021) Cite this article

Abstract

Pruritus is one of the most common symptoms experienced by neoplastic patients. The pathogenesis of neoplastic itch is complex and multifactorial and could be due to an unbalanced production of humoral mediators by altered immune effector cells. IL-31 is a pro-inflammatory cytokine produced by CD4 + T helper cells. The aim of this review was to evaluate the role of this Th2 cytokine and its receptor IL-31RA, in the onset of neoplastic pruritus. We analysed scientific literature looking for the most relevant original articles linking IL-31to itch in oncologic diseases. Interleukin-31 seems to be a main itch mediator in several hematologic disease such as Cutaneous T cells lymphomas. In these patients IL-31 was positively linked to itch level, and IL-31 matched with disease stage. IL-31 seems to play an important role in the signalling pathway involved in pruritus, but it is also suggested to play a proinflammatory and immunomodulatory role which could play a part in the progression of the neoplastic disease. Further studies will be fundamental in facing pruritus in oncologic patients, since this problem compromise their quality of life worsening an already critic picture.

Introduction

Pruritus is one of the most disabling symptoms in oncologic patients. It is typical of some diseases like Hodgkin’s lymphoma, leukaemia and cutaneous T-cell lymphoma and biliary cancer [1]. The above-described symptom can be categorized in two subtypes: the first is a direct consequence of the neoplasia in a particular tissue and the second is paraneoplastic. The last type of pruritus was defined by The Special Interest Group of the International Forum on the Study of Itch. They define paraneoplastic itch as a symptom provoked neither by the local presence of tumor cells nor by anti-cancer treatments. It is usually concomitant with the pathology progression or in some cases it can precede a hidden malignancy; once more, it is not caused by the physical presence of the mass and subsides after the recovery [2,3,4]. In this scenario, inflammatory mediators are fundamental causal agents of skin diseases and neoplastic-associated cutaneous signs. Often, these skin diseases are pruritic [5].

Among these, Cutaneous T cells lymphoma (CTCL) have been associated to augmented levels of pro-inflammatory cytokines and among these, a Th2 cytokine called interleukin 31 (IL-31) appeared particularly involved. Interleukin (IL)-31, a cytokine cloned by Dillon et al. in 2004, is primarily secreted by activated T cells, especially T helper Th2 cells (CD4 + CXCR3- CCR4 + CCR6-cells) [6]. Recently, it was reported that the IL-31 receptor is expressed in the peripheral nerves of mice and humans [7], suggesting that IL-31 secreted by Th2 cells may influence right peripheral nerves, triggering the pruritus linked to atopic dermatitis (AD).

This cytokine, in fact, belong to the IL-6 family, and have been frequently associated to pruritic skin diseases [6]. CD45RO + cutaneous T lymphocytes are responsible for IL-31 production. Its receptor is IL-31R, which is heterodimeric and ubiquitously represented. It has 2 subunits, the IL-31 receptor alpha (IL-31RA) and the oncostatin-M receptor beta (OSMR). These two subunits are expressed by IL-31-activated monocytes [8]. Firstly IL-31 was thought to be secreted only by Th2 and Th1 lymphocytes; recently also mast cells were reported being capable of producing IL-31, as well as monocytes, macrophages, and monocyte-derived dendritic cells and human mast cells. According to these data, innate and adaptive immunity appear to be linked to this interleukin role, in particularly when skin is involved [9,10,11]. More specifically, intracellular signaling involving the IL-31receptor by IL-31 is facilitated by the Janus kinase (JAK)-signal transducer and activator of transcription (STAT), phosphatidylinositol-3 kinase (PI3K)/AKT, and mitogen-activated protein kinase (MAPK) pathways [12, 13]. The lone phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) is not sufficient to stimulate JAK1/JAK2 and STAT3 [14]. Additionally, it was observed that missense mutations in the OSMR β gene were isolated in patients of familial primary localized cutaneous amyloidosis (FPLCA), hereditary skin disease associated with severe pruritus and deposition of amyloid material in the dermis [15, 16]. OSMRβ is a component of IL-31R and OSM type II receptor. FPLCA keratinocytes were stimulated with OSM and IL-31, the expression levels of phosphorylated STATs, ERK1/2, and AKT were diminished. JAK/STAT, ERK1/2 and PI3K/AKT signaling pathway have anti-apoptotic effect in several tumor cell lines; so apoptosis and accumulation of degenerate keratinous material deposition in the dermis are a possibility in the OSMRβ mutated FPLCA patients. These data indicated that OSM and IL-31 signaling are involved in keratinocyte cell proliferation, differentiation, apoptosis and inflammation [17].

Skin alteration were associated to IL-31 and in every disease the immune system acted a main role: atopic dermatitis (AD), allergic contact dermatitis, prurigo nodularis, and chronic urticaria are some examples. In every pathology itch was present [18, 19].

Circulating IL-31 was directly connected with the severity of itch in a neoplastic disease such as CTCL. In this condition, the mediator was found being released by malignant CD4 + T cells lacking CD26 expression, as well as by cells marked by antibodies against the beta chain variable region (Vβ) of the T cell receptor [20].

Inflammatory and malignant pruritic skin diseases have an association with Th2 cells and for this reason we aimed to review the interplay between Th2 cells, IL-31, and pruritus in malignancies (Fig. 1)

Fig. 1
figure 1

Etiopathogenesis of itch in malignancies linked IL-31

Full size image

Methods

This review was conducted using PubMed database and Google Scholar. A comprehensive search was accomplished employing the following query (date of last search, February 2021): (#1 IL-31; AND #2 Pruritus; OR #3 itch; AND #4 Leukemia, Myeloid, Acute [MH] OR #4 Chronic Myeloid Leukemia; OR # 5 Lymphoma [MH]; OR #6 Cutaneous T cell lymphoma; OR #7 Cancer; OR 8# Malignacies. We included only research articles in English.

In the first phase, titles and abstracts were examined by two researchers, according to precise criteria stated, to regulate this systematic review. Any divergence was decided by a third, independent researcher. We included papers presenting data about the role of IL-31 in the onset of pruritus. In the next phase, full texts of the selected articles were evaluated, and references of included papers were examined to find further works.

The information was then summarized and organized in the present review.

On these websites, we employed as key terms: IL-31, pruritus, itch, cancer, malignancies, Cutaneous T cell lymphoma and leukemia. The selected articles were retrieved in Table 1.

Table 1 List of the research articles evaluating IL-31 levels in patients with cancer and pruritus
Full size table

Results

Cutaneous T cells lymphoma

Primary cutaneous T-cell lymphomas (CTCLs) account for approximately two-thirds of all primary cutaneous lymphomas [21], with mycosis fungoides (MF) and Sézary syndrome (SS) being the most common subtypes. Both MF and SS are characterized by a monoclonal proliferation of mature T helper lymphocytes in the skin. Tumor cells in MF are classically CD3+CD4+CD8−, with frequent loss of CD7 [22]. Pruritus is typical of most advanced stages of CTCL; often the symptom compromise patients life quality [21]. Th2 cytokines are involved in CTCL pathogenesis of pruritus and include IL-4, IL-5 and IL-13, together with eosinophilia and IgE [23].

Nattkemper et al. [24] studied for the first time the expression levels and patterns of IL-31 and both of its receptors within the skin of CTCL subjects with pruritus. According to their data IL-31 was positively linked to itch level. However, IL-31 did not match with disease stage. Probably, IL-31 is not fundamental for the pathogenesis of CTCL. One study bias was the low number of early stages CTCL subjects; moreover, CTCL patients without pruritus were totally missing. IL-31RA and oncostatin-M receptor beta (OSMRβ) were highly expressed too. IL-31 was significantly increased in skin and in the lymphocytic infiltrate, but on the other side, its receptors were augmented only in the epidermis.

Also Ohmatsu et al. [25] demonstrated augmented circulating IL-31 in CTCL; but also they demonstrated the presence of several cytokines (i.e. IL-4 and IL-6) and chemokines (i.e. CXCL12, CXCL13, CCL17 and CCL26) fundamental in CTCL which might be modulated by IL-31. In this case CTCL was as severe as IL-31 was higher. Serum sIL-2R and lactate dehydrogenase (LDH) were also correlated to the severity.

In another report, 40 patients had a statistically significant variation in IL-31 levels between patients affected by itch and non-pruritic subjects. According to the authors CD4 + CD26- malignant cells specifically released IL-31. Finally the withdrawal of the itching sensation was correlated to lower levels of serum IL-31 [20].

The study by Malek et al. reached partially different conclusions. IL-31 was higher in advanced stages (IV) of CTCL the in earlier (IA). There was a low correlation between serum IL-31 concentration and pruritus in the whole patients. These contrasting data versus other studies, were probably due to the different severity of the subjects considered [26].

Blocking IL-31 improved itch in patients with advanced stages of CTCL. Dexamethasone and vorinostat reduced IL-31 levels and their producing cells with no effects on other malignant T cells highlighting the interleukin importance in pruritus pathogenesis but not in the disease [12].

Follicular lymphoma

Follicular lymphoma (FL) is a systemic neoplasia of the lymphoid tissue characterized by germinal center (GC)-derived B cell malignancy and differentiation. It constitute about the 5% of all hematologic malignancies and about the 20–25% of the new diagnosed non-Hodgkin lymphoma in the industrialized countries [27].

Ferretti et al. reported the first data about the IL-31/IL-31R complex in B-cell lymphomas [11]. They analysed this mature B-cell malignancy, which is the second most frequent B-cell lymphoma after large B-cell lymphoma. They noticed that IL-31 and its receptor have a paracrine/autocrine role in favouring FL progression. Both CD4 T cells and CD68 macrophages were found capable of producing IL-31.

Hodgkin lymphoma

Hodgkin Lymphoma (HL) is a B cell-malignancy with low ratio of neoplastic mono-nucleated Hodgkin and multi-nucleated Reed-Stenberg (H/RS) cells in the invaded lymph nodes [28]. These cells are influenced by the interplay between tumour cells and reactive cells accumulating in HL-involved tissues. These non‐malignant cells, recruited and/or induced to proliferate by tumour cells, release soluble or membrane‐molecules with a role in malignant cells growth and survival [29].

Surface and cytoplasmic IL-31 and thymic stromal lymphopoietin (TSLP) and their receptors were studied in H/RS cells. Lymph node microenvironment with immune and malignant cells coexisting with these mediators give an idea of the complexity of this interaction. In this scenario, the authors did not find augmented levels of IL-31 in the overall patients group respect to healthy subjects. However, both levels of the interleukin and of the pruritogenic cytokine TSLP appeared to be intimately linked. The authors found no association between itch and IL-31 and between disease stage and IL-31 in HL subjects. However, in patients with a worst prognosis they found higher levels of sIL-31 and sTSLP compared to those with a better possible outcome. This difference suggested a prognostic potential of these parameters [30].

Chronic myeloid leukemia

Imatinib mesylate belong to the family of the tyrosine kinase inhibitor (TKi); it’s commonly used for the treatment of chronic myeloid leukemia (CML). Skin disorders were considered a direct effect of the drug rather than an adverse reaction [31, 32]. We performed a study on a CML patient with an intense pruritus developed after Imatinib mesylate administration. The patient had elevated plasma levels of both IL-31 and IL-33. We speculated that TKi could directly provoke keratinocyte disruption releasing IL-33, which in turn activated an inflammatory cascade responsible for involving IL-31 and causing skin damages [19].

Discussion

Interleukin-31, pruritus and the CTCL model

Evaluating IL-31 role in pruritus pathogenesis have to necessarily consider both the plasmatic interleukin and its relative receptors: IL-31 receptor A and the oncostatin M receptor [33]. IL-31 receptor A is mainly represented on the sensory dorsal root ganglion; on the other side, oncostatin M receptor was linked to pruritus due to its connection with cutaneous amyloidosis. Also, IL-31 mRNA had a key role in pruritus since it high levels in pathologies intimately linked to it: atopic dermatitis, allergic contact dermatitis and prurigo nodularis [18]. Moreover, the interleukin is also correlated with the severity of the diseases [34]. IL-31 role in CTCL was confirmed by the above cited studies, where the mediator was often correlated with advanced stages of the disease in symptomatic patients [20, 26]. Contrasting data about earlier and latter stages may be due to the Th response; in the first phase of the disease in fact, there is a predominance of Th1 phenotype. It is known that IL-31 is produced mainly by Th2 lymphocytes and this is typical of advanced stages of CTCL [10]. Once more, high blood levels of IL-31 were linked to pruritus intensity and serum and tissue expression of the chemokine CCL18 [35]. IL-31 was also found to be augmented in advanced stages of mastocytosis and the immunohistochemical analyses of bone marrow confirmed that tryptase-positive mast cells as were the major source of the interleukin [36]; in addition some IL-31 gene polymorphisms were reported to amplify both mast cells involvement and pruritus [37]. Continuing talking about Th2 cytokines, Stott et al. [35] demonstrated that IL-31 expression is modulated by IL-4. According to their data, the blocking of IL-4 from a Th2 environment diminished the levels of IL-31. Several authors also showed the induction of IL-31 by IL-33 [19, 35]. Moreover, it is thought that IL-31 can induce keratinocytes and infiltrating cells to release additional mediators involved in pruritus. Furthermore, IL-31 has also been shown to cause the release of pro-inflammatory cytokines from eosinophils, monocytes, and macrophages [38]. The IL-31/33 axis role in pruritus in malignancies should be deeply investigated. Finally, patients affected by CTCL with skin disorders were demonstrated to express Th2 cytokines in their lesions: IL-4, 5, 6, 9, 10,13, 31 (and its receptors) and 33. Th2 expression augment in consideration of disease stage and this could in part explain pruritus progression [39].

These results give birth to the need of more studies about IL-31 role in malignant itch. For these conflicting data, new research need to investigate the role of IL-31 in pruritus associated to malignancies.

The neuro-immune hypothesis

IL-31 seems to induce pruritus by directly stimulating IL-31RA on TRPV11/ TRPA11 sensory nerves in the skin [7]. IL-31 and that the number and activation of Th2 cells, were augmented in human and animal models of AD suggesting a neuroimmune cycle involving Th2 cells, and IL-31RA on sensory nerves that seems applicable on the neoplastic model. On the other hand, the other IL-31 receptor, OSMRb was not elevated suggesting a minor importance in provoking itch. Some researchers proposed the hypothesis that IL-31RA might be considered a functional neural cytokine receptor [7]. One of the most used drugs in order to control pruritus, also in oncology, are anti-histamines but this speculation emphasizes that not only mast cells through histamine or tryptase [40] but also T cells through IL-31 could straight stimulate sensory nerves [7].

The nervous system involvement was endorsed by dorsal root ganglia (DRG) expression of IL-31 and IL-31RA after the cutaneous administration of the interleukin capable of provoking pruritus [41].

Conclusions

Itch is often associated to cancer. It could be mainly associated to 3 situations. First, it could represent the first signal of the tumor presence and constitute a paraneoplastic syndrome. Its causative factor is the systemic release of oncologic mediators. Second, pruritus could be generated by the physical presence of the malignant mass. Third, itch could be a consequence of anti-neoplastic drugs. We described a potential fourth actor in the scenario constituted by an oncologic patient: an interleukin capable of provoking pruritus without being part of the first three pathways described above.

The data collected in this review showed that high IL-31 levels and its receptors are correlated to skin pruritus in malignant disease. The most studied model was CTCL, where the pathogenetic mechanism seems to be emblematic. The researches collected together with other reports were not able to clarify if interleukin 31 is connected to the itch, to the cancer or to both [42]. These data are encouraging in respect to a potential anti-pruritic treatment based on reducing IL-31 or its receptor IL-31RA. Nemolizumab, as a monoclonal antibody against this interleukin, demonstrated its efficacy in controlling pruritus in other diseases and offers a hope for oncologic patients [43,44,45,46]. However, CTCL is not the only malignant disease existing. In fact, one of the messages of this review is to stimulate researchers in linking itch in various type of cancer and testing the role of the “skin neuroimmune cytokine” IL-31. Results will be fundamental in facing pruritus in oncologic patients, since this problem compromise their quality of life worsening an already critic picture.

Availability of data and materials

Not applicable.

References

  1. Polat M, Öztas P, \.Ilhan N, Yalçin M, Alli B. Generalized pruritus. Am J Clin Dermatol. 2008;9:39–44.

    Article  PubMed  Google Scholar 

  2. Weisshaar E, Weiss M, Mettang T, Yosipovitch G, Zylicz Z. Paraneoplastic itch: an expert position statement from the special interest group (SIG) of the International Forum on the Study of Itch (IFSI). Acta Derm Venereol. 2015;95:261–5.

    Article  PubMed  Google Scholar 

  3. Yosipovitch G. Chronic pruritus: a paraneoplastic sign. Dermatol Ther. 2010;23:590–6.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Rowe B, Yosipovitch G. Malignancy-associated pruritus. Eur J Pain. 2015;20:19–23.

    Article  PubMed  CAS  Google Scholar 

  5. Bilsborough J, Leung DYM, Maurer M, Howell M, Boguniewcz M, Yao L, Storey H, LeCiel C, Harder B, Gross JA. IL-31 is associated with cutaneous lymphocyte antigen–positive skin homing T cells in patients with atopic dermatitis. J Allergy Clin Immunol. 2006;117:418–25.

    Article  CAS  PubMed  Google Scholar 

  6. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004;5:752–60.

    Article  CAS  PubMed  Google Scholar 

  7. Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1. Journal of Allergy Clinical Immunology. 2014;133:448-60.e7.

    Article  CAS  Google Scholar 

  8. Di Salvo E, Ventura-Spagnolo E, Casciaro M, Navarra M, Gangemi S. IL-33/IL-31 axis: a potential inflammatory pathway. Mediat Inflam. 2018.

  9. Cornelissen C, Lüscher-Firzlaff J, Baron JM, Lüscher B. Signaling by IL-31 and functional consequences. Eur J Cell Biol. 2012;91:552–66.

    Article  CAS  PubMed  Google Scholar 

  10. Ferretti E, Corcione A, Pistoia V. The IL-31/IL-31 receptor axis: general features and role in tumor microenvironment. J Leukoc Biol. 2017;102:711–7.

    Article  CAS  PubMed  Google Scholar 

  11. Ferretti E, Tripodo C, Pagnan G, et al. The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. Leukemia. 2014;29:958–67.

    Article  PubMed  CAS  Google Scholar 

  12. Zhang Q, Putheti P, Zhou Q, Liu Q, Gao W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor Rev. 2008;19:347–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  13. Hermanns HM. Oncostatin M and interleukin-31: cytokines, receptors, signal transduction and physiology. Cytokine Growth Factor Rev. 2015;26:545–58.

    Article  CAS  PubMed  Google Scholar 

  14. Maier E, Mittermeir M, Ess S, Neuper T, Schmiedlechner A, Duschl A, Horejs-Hoeck J. Prerequisites for functional Interleukin 31 signaling and its feedback regulation by suppressor of cytokine signaling 3 (SOCS3) *. J Biol Chem. 2015;290:24747–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Arita K, South AP, Hans-Filho G, et al. Oncostatin M receptor-β mutations underlie familial primary localized cutaneous amyloidosis. Am J Human Genet. 2008;82:73–80.

    Article  CAS  Google Scholar 

  16. Tanaka A, Arita K, Lai-Cheong JE, Palisson F, Hide M, McGrath JA. New insight into mechanisms of pruritus from molecular studies on familial primary localized cutaneous amyloidosis. Br J Dermatol. 2009;161:1217–24.

    Article  CAS  PubMed  Google Scholar 

  17. Nakashima C, Otsuka A, Kabashima K. Interleukin-31 and interleukin-31 receptor: new therapeutic targets for atopic dermatitis. Exp Dermatol. 2018;27:327–31.

    Article  CAS  PubMed  Google Scholar 

  18. Sonkoly E, Muller A, Lauerma AI, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117:411–7.

    Article  CAS  PubMed  Google Scholar 

  19. Musolino C, Allegra A, Mannucci C, Russo S, Alonci A, Maisano V, Calapai G, Gangemi S. Possible role of interleukin-31/33 axis in imatinib mesylate-associated skin toxicity. Turk J Hematol. 2015;32:168–71.

    Article  Google Scholar 

  20. Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-cell lymphoma and correlates with CTCL pruritus. J Investig Dermatol. 2013;133:2783–5.

    Article  CAS  PubMed  Google Scholar 

  21. Cedeno-Laurent F, Singer EM, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158:1–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol. 2012;67:760–8.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Quandt D, Fiedler E, Boettcher D, Marsch WC, Seliger B. B7-H4 expression in human melanoma: its association with patients\textquotesingle survival and antitumor immune response. Clin Cancer Res. 2011;17:3100–11.

    Article  CAS  PubMed  Google Scholar 

  24. Nattkemper L, Martinez-Escala M, Gelman A, Singer E, Rook A, Guitart J, Yosipovitch G. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm Venereol. 2016;96:894–8.

    Article  CAS  PubMed  Google Scholar 

  25. Ohmatsu H, Sugaya M, Suga H, et al. Serum IL-31 levels are Increased in patients with cutaneous T-cell lymphoma. Acta Derm Venereol. 2012;92:282–3.

    Article  CAS  PubMed  Google Scholar 

  26. Malek M, Gleń J, Rębała K, Kowalczyk A, Sobjanek M, Nowicki R, Ruckemann-Dziurdzińska K, Sokołowska-Wojdyło M. Il-31 does not correlate to pruritus related to early stage cutaneous T-cell lymphomas but is involved in pathogenesis of the disease. Acta Derm Venereol. 2015;95:283–8.

    Article  CAS  PubMed  Google Scholar 

  27. Carbone A, Roulland S, Gloghini A, Younes A, von Keudell G, López-Guillermo A, Fitzgibbon J. Follicular lymphoma. Nat Rev Dis Primers. 2019. https://doi.org/10.1038/s41572-019-0132-x.

    Article  PubMed  Google Scholar 

  28. Küppers R. The biology of Hodgkin’s lymphoma. Nat Rev Cancer. 2008;9:15–27.

    Article  PubMed  CAS  Google Scholar 

  29. Aldinucci D, Gloghini A, Pinto A, Filippi RD, Carbone A. The classical Hodgkin’s lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221:248–63.

    Article  CAS  PubMed  Google Scholar 

  30. Ferretti E, Hohaus S, Napoli AD, et al. Interleukin-31 and thymic stromal lymphopoietin expression in plasma and lymph node from Hodgkin lymphoma patients. Oncotarget. 2017;8:85263–75.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Brouard MC, Prins C, Mach-Pascual S, Saurat J-H. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology. 2001;203:57–9.

    Article  CAS  PubMed  Google Scholar 

  32. Drummond A, Micallef-Eynaud P, Douglas WS, Murphy JA, Hay I, Holyoake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (sti 571, glivec®). Br J Haematol. 2003;120:911–3.

    Article  CAS  PubMed  Google Scholar 

  33. Raap U, Wichmann K, Bruder M, Ständer S, Wedi B, Kapp A, Werfel T. Correlation of IL-31 serum levels with severity of atopic dermatitis. J Allergy Clin Immunol. 2008;122:421–3.

    Article  CAS  PubMed  Google Scholar 

  34. Allegra A, Salvo ED, Casciaro M, Musolino C, Pioggia G, Gangemi S. The impact of immunological checkpoint inhibitors and targeted therapy on chronic pruritus in cancer patients. Biomedicines. 2020;9:2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  35. Stott B, Lavender P, Lehmann S, Pennino D, Durham S, Schmidt-Weber CB. Human IL-31 is induced by IL-4 and promotes TH2-driven inflammation. J Allergy Clin Immunol. 2013;132:446-54.e5.

    Article  CAS  PubMed  Google Scholar 

  36. Hartmann K, Wagner N, Rabenhorst A, Pflanz L, Leja S, Förster A, Gehring M, Kapp A, Raap U (2013) Serum IL-31 levels are increased in a subset of patients with mastocytosis and correlate with disease severity in adult patients. J Allergy Clin Immunol 132:232–235

    Article  CAS  PubMed  Google Scholar 

  37. Lange M, Gleń J, Zabłotna M, et al. Interleukin-31 polymorphisms and serum IL-31 level in patients with mastocytosis: correlation with clinical presentation and pruritus. Acta Derm Venereol. 2017;97:47–53.

    Article  CAS  PubMed  Google Scholar 

  38. Kasraie S, Niebuhr M, Werfel T. Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy. 2009;65:712–21.

    Article  PubMed  CAS  Google Scholar 

  39. Meyer N, Paul C, Misery L. Pruritus in cutaneous T-cell lymphomas: frequent, often severe and difficult to treat. Acta Derm Venereol. 2010;90:12–7.

    Article  CAS  PubMed  Google Scholar 

  40. Steinhoff M, Vergnolle N, Young SH, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med. 2000;6:151–8.

    Article  CAS  PubMed  Google Scholar 

  41. Arai I, Tsuji M, Miyagawa K, Takeda H, Akiyama N, Saito S. Repeated administration of IL-31 upregulates IL-31 receptor A (IL-31RA) in dorsal root ganglia and causes severe itch-associated scratching behaviour in mice. Exp Dermatol. 2014;24:75–8.

    Article  PubMed  CAS  Google Scholar 

  42. Olszewska B, Soko\lowska-Wojdy\lo M, Lakomy J, Nowicki R. The ambiguous pruritogenic role of interleukin-31 in cutaneous T-cell lymphomas in comparison to atopic dermatitis: a review. Adv Dermatol Allergol. 2020;37:319–25.

    Article  Google Scholar 

  43. Oyama S, Kitamura H, Kuramochi T, et al. Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody. Exp Dermatol. 2018;27:14–21.

    Article  CAS  PubMed  Google Scholar 

  44. Nemoto O, Furue M, Nakagawa H, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174:296–304.

    Article  CAS  PubMed  Google Scholar 

  45. Kabashima K, Matsumura T, Komazaki H, Kawashima M, Nemolizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383:141–50.

    Article  CAS  PubMed  Google Scholar 

  46. Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, Etoh T, Mihara R, Nakano M, Ruzicka T. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142:1121-30.e7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

None.

Author information

Authors and Affiliations

  1. Department of Veterinary Sciences, University of Messina, 98168, Messina, Italy

    Eleonora Di Salvo

  2. Division of Hematology, Department of Human Pathology in Adulthood and Childhood “Gaetano Barresi”, University of Messina, 98125, Messina, Italy

    Alessandro Allegra

  3. School and Operative Unit of Allergy and Clinical Immunology, Department of Clinical and Experimental Medicine, University of Messina, 98125, Messina, Italy

    Marco Casciaro & Sebastiano Gangemi

Authors
  1. Eleonora Di Salvo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Allegra
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marco Casciaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sebastiano Gangemi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, SG; methodology, SG and AA; software, MC; formal analysis, EDS, MC; investigation, EDS, MC; resources, SG; data curation, AA; writing—original draft preparation, EDS, MC; writing—review and editing EDS, AA; visualization, MC; supervision, AA and SG; project administration, SG. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Marco Casciaro.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

None of the author have any conflict of interests to declare.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Di Salvo, E., Allegra, A., Casciaro, M. et al. IL-31, itch and hematological malignancies. Clin Mol Allergy 19, 8 (2021). https://doi.org/10.1186/s12948-021-00148-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12948-021-00148-7

Keywords

  • IL-31
  • IL-33
  • Itch
  • Pruritus
  • Malignancies
  • Cancer
  • Cytokines
  • Skin

Clinical and Molecular Allergy

ISSN: 1476-7961

Contact us